Takeda says won't bid for Solvay pharma unit
TOKYO (Reuters) - Takeda Pharmaceutical Co, Japan's largest drugmaker, said it would not bid for the pharmaceutical unit of Belgian chemicals, plastics and drugs company Solvay SA.
Solvay is set to receive a range of proposals for its pharmaceutical unit by Friday's deadline for indicative bids and Takeda was thought to be among the likely bidders, people familiar with the matter had told Reuters.
A Takeda spokesman said the company was not considering a bid for the unit.
Analysts have said the business, whose research focuses heavily on cardiometabolic and neurological treatments, could fetch 5 billion euros ($7 billion) or more.
(Reporting by Yumiko Nishitani and Nathan Layne)
BOSTON - Hedge fund manager William Ackman, who is betting $1.16 billion that Herbalife is a fraud, spent $264,000 last year on lobbyists to press his case against the company, according to government documents filed in recent weeks.
- U.S. small businesses borrowed more money in January than they did a year earlier, signaling continued growth in the economy despite a spate of cold weather that has been blamed for weakness in many other indicators of activity.
BEIJING/HONG KONG - China reiterated its opposition on Thursday to a European Union plan to limit airline carbon dioxide emissions and called for talks to resolve the issue a day after its major airlines refused to pay any carbon costs under the new law.